Alliance for the Prudent Use of Antibiotics
The mission of the Alliance for the Prudent Use of Antibiotics (APUA) is to strengthen global defenses against infectious disease by ensuring access to effective treatment and promoting appropriate antibiotic use to contain drug resistance. With a network of affiliated chapters in 16 countries, APUA stands as the world’s leading organization conducting research and education on antimicrobial treatment and resistance at the grassroots and global levels.
- APUA endorses S-FAR letter to new CDC Director Fitzgerald
- APUA’s 2014 Leadership Award winner turns spotlight on the search for natural antimicrobials
- EU adopts a One Health Action Plan against Antimicrobial Resistance (AMR)
- G20 summit commits to combatting antimicrobial resistance
- CRE light up with new fluorescence based assay
- Novel CRISPR innovation increases discrimination of dangerous pathogens
- Re-engineering longevity into vancomycin
- New antibiotics (iclaprim, omadacycline) pass phase III clinical studies
- Bacteriophage therapy saves U.S. patient with multidrug-resistant bacteria
- Immune system-based peroxidases explored as new antimicrobials
- Bioluminescent bacteria recruited to find antimicrobials in New Zealand fungus
- Synthetic mucus shows promise against antimicrobial resistant organisms
- Experts rethink failed hygiene strategy
- Hospital Microbiome Project seeks clues to better hygiene interventions
- Overall resistance in Staph aureus declines in U.S. hospitals; serious infections remain constant
- “Resistomap” showcases resistance data from global human gut microbiomes
- Crowd funding study approach used to solicit ESBL study data
- INCREMENT project yields findings on BSI treatment
- Stewardship expert shares tips on implementing new required plans
- Publications and Webinars of Note
APUA WELCOMES NEW BOARD MEMBERS
APUA is proud to announce the addition of five new members to our Board of Directors:
- Robert Gaynes, MD, Professor - Department of Medicine - Emory School of Medicine
- Shahin Gharakhanian, MD - Cambridge Innovation Center
- Cristina Larkin, Chief Commercial Officer - Spero Therapeutics
- Margaret Riley, PhD, Professor - Department of Biology - University of Massachusetts, Amherst
- David White, PhD, Associate Dean of Research - University of Tennessee School of Agriculture
You can view the complete list of APUA Board members
APUA extends its deepest thanks to Dennis Signorovitch as he completes 10 years of outstanding service as a member of APUA's Board of Directors. His leadership, advice and enthusiasm have aided the organization immeasurably in forwarding its mission and we wish him well in all his future endeavors. Thank you, Dennis!
Antibiotics are humanity's key defense against disease-causing microbes. The growing prevalence of antibiotic resistance threatens a future where these drugs can no longer cure infections and killer epidemics run rampant. The Alliance for the Prudent Use of Antibiotics (APUA) has been the leading global non-governmental organization fighting to preserve the effectiveness of antimicrobial drugs since 1981. With affiliated chapters in over 66 developed and developing countries, we conduct research, education and advocacy programs to control antimicrobial resistance and ensure access to effective antibiotics for current and future generations. For more information on antibiotic resistance research, visit our partner lab at the Center for Adaptation Genetics and Drug Resistance.
"Antibiotics are uniquely societal drugs because individual use affects others in the community and environment. Better stewardship, incentives, and establishment of a special regulatory category will improve how they are used, marketed, and developed through incentives to industry."
Stuart B. Levy, M.D.
President of APUA, professor at Tufts University School of Medicine
From the IOM 25th Anniversary Symposium (1996) and The Antibiotic Paradox (2002)
In case you missed it, our latest webinar
is now available for streaming.